Related Experiment Videos

Presence and density of common bile duct microlithiasis in acute biliary pancreatitis

Maciej Kohut1, Andrzej Nowak, Ewa Nowakowska-Duiawa

  • 1Department of Gastroenterology, Central Clinical Hospital, Silesian Academy of Medicine, Medyk w 14,40 - 752 Katowice, Poland. maciej.2250177@pharmanet.com.pl

Abstract

Insights

Common bile duct microlithiasis (CBDM) is frequently found in acute biliary pancreatitis (ABP) patients without stones. This study suggests CBDM may cause ABP, especially when detected early with high crystal density.

Area of Science:

  • Gastroenterology
  • Hepatology
  • Biliary System Diseases

Background:

  • Common bile duct microlithiasis (CBDM) is prevalent in acute biliary pancreatitis (ABP) patients lacking detectable CBD stones during ERCP.
  • The etiological role of CBDM in ABP remains uncertain, with debate on whether it's a cause or consequence.

Purpose of the Study:

  • To investigate the presence and density of CBDM in ABP patients.
  • To assess how CBDM prevalence and crystal density vary with the time elapsed since disease onset.

Main Methods:

  • Prospective study of 151 consecutive ABP patients without CBD stones on urgent ERCP.
  • Bile analysis during ERCP to quantify cholesterol monohydrate crystals (CMCs) and calcium bilirubinate granules (CBGs).
  • Defined high crystal density as >10 CMCs and/or >25 CBG clusters per slide.

Main Results:

  • CBDM was detected in 88.2% on day 1-3, decreasing to 68.6% by day 4-7 (P=0.018).
  • High crystal density was observed in 90% on day 1-3, reducing to 66.7% by day 4-7 (P=0.039).
  • Both prevalence and density of CBDM were highest in the initial disease phase.

Conclusions:

  • CBD microlithiasis is present in most ABP patients without common bile duct stones, particularly early in the disease course.
  • The high prevalence and density of CBDM during the initial phase suggest it may be a causative factor in ABP rather than a result.

Related Concept Videos